ReviewCancers2025
Artificial Intelligence and Machine Learning in Lung Cancer: Advances in Imaging, Detection, and Prognosis.
Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
BACKGROUND/
objectivesAs the primary cause of cancer-related death globally, lung cancer highlights the critical need for early identification, precise staging, and individualized treatment planning. By enabling automated diagnosis, staging, and prognostic evaluation, recent developments in artificial intelligence (AI) and machine learning (ML) have completely changed the treatment of lung cancer. The goal of this narrative review is to compile the most recent data on uses of AI and ML throughout the lung cancer care continuum.
methodsA comprehensive literature search was conducted across major scientific databases to identify peer-reviewed studies focused on AI-based imaging, detection, and prognostic modeling in lung cancer. Studies were categorized into three thematic domains: (1) detection and screening, (2) staging and diagnosis, and (3) risk prediction and prognosis.
resultsConvolutional neural networks (CNNs), in particular, have shown significant sensitivity and specificity in nodule recognition, segmentation, and false-positive reduction. Radiomics-based models and other multimodal frameworks combining imaging and clinical data have great promise for forecasting treatment outcomes and survival rates. The accuracy of non-small-cell lung cancer (NSCLC) staging, lymph node evaluation, and malignancy classification were regularly improved by AI algorithms, frequently matching or exceeding radiologist performance.
conclusionsThere are still issues with data heterogeneity, interpretability, repeatability, and clinical acceptability despite significant advancements. Standardized datasets, ethical AI implementation, and transparent model evaluation should be the top priorities for future initiatives. AI and ML have revolutionary potential for intelligent, personalized, and real-time lung cancer treatment by connecting computational innovation with precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.